Profile data is unavailable for this security.
About the company
Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj’s business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group’s strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.
- Revenue in EUR (TTM)2.29m
- Net income in EUR-21.67m
- Incorporated2015
- Employees174.00
- LocationNanoform Finland OyjCultivator II, Viikinkaari 4HELSINKI 00790FinlandFIN
- Phone+358 293700150
- Fax+358 88706970
- Websitehttps://nanoform.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcticzymes Technologies ASA | 9.92m | 1.25m | 75.69m | 68.00 | 60.49 | 2.78 | 42.69 | 7.63 | 0.2867 | 0.2867 | 2.27 | 6.24 | 0.3485 | 0.5349 | 6.83 | 1,706,250.00 | 4.39 | 15.58 | 4.63 | 17.22 | 94.39 | 96.69 | 12.60 | 33.23 | 17.25 | -- | 0.0298 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Alligator Bioscience AB | 4.02m | -20.63m | 88.24m | 51.00 | -- | -- | -- | 21.93 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Egetis Therapeutics AB (publ) | 8.27m | -26.10m | 118.25m | 32.00 | -- | 3.34 | -- | 14.30 | -1.23 | -1.23 | 0.3884 | 1.37 | 0.1496 | 13.45 | 7.48 | 3,477,778.00 | -33.65 | -33.02 | -40.07 | -36.46 | 92.12 | -- | -224.92 | -357.72 | 1.55 | -24.39 | 0.2158 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -18.91m | 118.76m | 26.00 | -- | 2.48 | -- | -- | -7.05 | -7.05 | 0.00 | 19.79 | 0.00 | -- | -- | 0.00 | -33.11 | -18.38 | -36.76 | -19.26 | -- | -- | -- | -- | 3.50 | -- | 0.0496 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Diamyd Medical AB | 16.38k | -12.29m | 123.46m | 25.00 | -- | 7.39 | -- | 7,537.94 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Nightingale Health Oyj | 3.65m | -18.06m | 133.33m | 81.00 | -- | 2.22 | -- | 36.49 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Vicore Pharma Holding AB | 9.18m | -17.62m | 138.13m | 28.00 | -- | 1.85 | -- | 15.05 | -1.76 | -1.76 | 0.9134 | 3.79 | 0.2546 | -- | 64.15 | 4,343,459.00 | -48.87 | -58.65 | -53.82 | -65.58 | -- | -- | -191.92 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Nanoform Finland Oyj | 2.29m | -21.67m | 140.10m | 174.00 | -- | 1.98 | -- | 61.06 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Nykode Therapeutics ASA | 5.50m | -33.91m | 152.97m | 179.00 | -- | 1.12 | -- | 27.82 | -1.27 | -1.27 | 0.2011 | 4.87 | 0.0333 | -- | 1.59 | 371,776.30 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Cereno Scientific AB | 0.00 | -6.12m | 154.01m | 5.00 | -- | 6.92 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Devyser Diagnostics AB | 17.26m | -4.77m | 180.71m | 127.00 | -- | 5.57 | -- | 10.47 | -3.33 | -3.33 | 12.05 | 22.35 | 0.3855 | 1.61 | 5.42 | 1,661,017.00 | -10.68 | -8.97 | -12.15 | -10.15 | 83.11 | 80.14 | -27.70 | -23.91 | 4.01 | -- | 0.1498 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Data as of Sep 20 2024. Currency figures normalised to Nanoform Finland Oyj's reporting currency: Euro EUR
31.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Aug 2024 | 6.10m | 7.13% |
| Fj�rde AP-fondenas of 29 Jan 2024 | 3.72m | 4.34% |
| Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 29 Jan 2024 | 3.07m | 3.59% |
| Keel Capital ABas of 31 Dec 2023 | 3.04m | 3.56% |
| ATP Arbejdsmarkedets Till�gspensionas of 31 Dec 2023 | 2.70m | 3.16% |
| Baillie Gifford & Co.as of 27 Mar 2023 | 1.87m | 2.19% |
| Danske Bank A/S (Investment Management Finland)as of 29 Jan 2024 | 1.84m | 2.16% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.73m | 2.02% |
| Keskin�inen El�kevakuutusyhti� Ilmarinenas of 29 Jan 2024 | 1.51m | 1.77% |
| Highclere International Investors LLPas of 31 Dec 2023 | 1.31m | 1.53% |
More ▼
Data from 31 Mar 2024 - 03 Sep 2024Source: FactSet Research Systems Inc.
